News | February 05, 2024
KIMS posts Q3 FY24 consolidated PAT at Rs. 71.84 Cr
KIMS has reported total income of Rs. 609.091 crores during the period ended December 31, 2023
KIMS has reported total income of Rs. 609.091 crores during the period ended December 31, 2023
Abbott India has reported total income of Rs. 1492.75 crores during the period ended December 31, 2023
Thyrocare Technologies has reported total income of Rs. 137.47 crores during the period ended December 31, 2023
Dr. Lal Path Labs has reported total income of Rs. 557.2 crores during the period ended December 31, 2023
GMM Pfaudler has reported total income of Rs. 848.28 crores during the period ended December 31, 2023
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Dabur India has reported total income of Rs. 3382.43 crores during the period ended December 31, 2023
Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023
Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Subscribe To Our Newsletter & Stay Updated
